Comprehensive Study Notes on Preterm Birth and Previable Birth

Definitions and Classifications of Preterm Birth

Preterm birth is defined as delivery occurring before 3737 completed weeks of gestation (specifically, before 366/736^{6/7} weeks). This condition constitutes a major global health challenge, affecting approximately 1515 million births worldwide annually. It is identified as the leading cause of death in children under the age of 55 years.

Terminology varies across leading health organizations:

  • American College of Obstetricians and Gynecologists (ACOG 2021b): Births between 3434 and 3636 completed weeks are "late preterm."
  • Centers for Disease Control and Prevention (CDC): Recognizes the late preterm definition but adds the label "early preterm" for births before 336/733^{6/7} weeks.
  • World Health Organization (WHO 2018):
    • Extremely Preterm: Births before 2828 completed weeks.
    • Very Preterm: Births from 2828 to 3232 weeks.
    • Moderate to Late Preterm: Births from 3232 to 3737 weeks.
Prematurity versus Preterm Birth

The concept of "preterm birth" (a temporal definition) must be distinguished from "prematurity," which refers to the functional state of incomplete organ system development at birth. A neonate born at 3535 weeks is "preterm" by definition, but may exhibit varying degrees of "prematurity" regarding lung function, such as susceptibility to respiratory distress syndrome (RDS).

Birthweight Classifications (WHO 2019)
  • Low Birthweight (LBW): Neonates weighing 15001500 to 2500 g2500\,g.
  • Very Low Birthweight (VLBW): Neonates weighing 10001000 to 1500 g1500\,g.
  • Extremely Low Birthweight (ELBW): Neonates weighing <1000 g< 1000\,g.

Preterm Birth Rate Trends and Demographics

In the United States, the preterm birth rate was measured at 10.02%10.02\% in 20182018, rising to 10.23%10.23\% in 20192019.

Data Interpretation and Dating Criteria

A shift in the National Center for Health Statistics (NCHS) standard occurred in 20142014. The calculation method for gestational age transitioned from the date of the last menstrual period (LMP) to the "obstetrical estimate" of gestational age at delivery. This change makes current national data not directly comparable to historical records before 20142014.

Trends and Disparities
  • Late-Preterm Influence: The overall rise in the U.S. preterm rate from 20182018 to 20192019 was driven primarily by an increase in late-preterm births (rates rising since 20132013).
  • Racial and Socioeconomic Disparities: Preterm birth rates among black women in the U.S. are markedly higher than those for white and Hispanic women. Factors such as differing socioeconomic circumstances and racial discrimination are cited as contributors.
  • Global Context: Preterm birth rates in the U.S. are higher than in other industrialized nations, though international rates are also trending upward.
  • Pregnancy Plurality: Singleton pregnancies should be analyzed separately, as multifetal gestations have a shorter average gestational length and naturally increase the overall preterm birth statistics.

Preterm Newborn Morbidity and Mortality

There is an inverse relationship between gestational age at delivery and the risk of neonatal morbidity and mortality. In 20182018, while early-preterm neonates formed the smallest proportion of births, they experienced disproportionately high complication rates.

Statistical Context
  • Preterm births accounted for 66%66\% of the 21,49821,498 infant deaths in the U.S. in 20182018.
  • The infant mortality rate for those born at <28< 28 weeks was 186186 times higher than for those born at 3737 to 4141 weeks.
  • Apgar scores at 55 and 1010 minutes in preterm neonates correlate with mortality; lower scores may reflect biological immaturity rather than fetal depression.
Survival Statistics by Weight and Age (Fanaroff 2007)

Survival rates reach 95%95\% when the neonate achieves:

  • Birthweight ≥1000 g\ge 1000\,g.
  • Gestational age ≥28\ge 28 weeks for females.
  • Gestational age ≥30\ge 30 weeks for males.
Short-term and Long-term Systemic Morbidities
  1. Pulmonary: RDS, bronchopulmonary dysplasia (BPD), apnea of prematurity, reactive airway disease, and asthma.
  2. Gastrointestinal: Hyperbilirubinemia, feeding intolerance, necrotizing enterocolitis (NEC), failure to thrive, and short-bowel syndrome.
  3. Immunological: Hospital-acquired infections, immune deficiency, and Respiratory syncytial virus (RSV).
  4. Central Nervous System: Intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), hydrocephalus, cerebral palsy, and neurodevelopmental delays.
  5. Ophthalmological: Retinopathy of prematurity (ROP), blindness, myopia, and strabismus.
  6. Cardiovascular: Hypotension, patent ductus arteriosus (PDA), and hypertension later in adulthood.
  7. Endocrinological: Hypoglycemia, cortisol deficiency, and increased insulin resistance.

The Threshold of Viability

The threshold of viability is defined as the lower limit of fetal maturation compatible with extrauterine survival. Currently, this falls between 200/720^{0/7} and 256/725^{6/7} weeks’ gestation.

Periviable Survival and Outcomes
  • <23< 23 Weeks: Often results in death; survival rates are approximately 55 to 10%10\%. Morbidity among survivors is significant.
  • 2222 to 2525 Weeks (University of Iowa Study): Survived neonates (excluding anomalous fetuses and parental request for palliation) showed mild or no neurodevelopmental impairment in 64%64\% of cases at 1818 to 2222 months, though survival at 2222 weeks was significantly lower than at 2424 weeks.
  • NICHD Neonatal Research Network: Survival rose from 30%30\% (epoch 20002000-20032003) to 36%36\% (epoch 20082008-20112011). However, only 1%1\% of infants born at 2222 weeks survived without neurodevelopmental impairment.
Clinical Management Guidance for Threatened Periviable Birth
  • <22< 22 Weeks: Resuscitation, corticosteroids, tocolysis, and magnesium sulfate are generally not recommended. Cesarean delivery is reserved for maternal indications only.
  • 220/722^{0/7} to 226/722^{6/7} Weeks: Resuscitation and fetal monitoring for delivery may be considered. Corticosteroids and tocolysis are generally not recommended.
  • 230/723^{0/7} to 236/723^{6/7} Weeks: Resuscitation, corticosteroids, tocolysis, and magnesium sulfate should be considered based on parental wishes and neonatal consult.
  • ≥240/7\ge 24^{0/7} Weeks: Resuscitation, corticosteroids, and tocolysis are recommended. Cesarean delivery for fetal indication is recommended after 250/725^{0/7} weeks.

Causes and Pathophysiology of Preterm Birth

Preterm birth is considered a heterogeneous syndrome activated by multiple disease processes rather than a single event. There are four major pathways identified in the United States:

  1. Spontaneous unexplained preterm labor with intact membranes (4040 to 45%45\%).
  2. Idiopathic preterm prelabor rupture of membranes (PPROM) (3030 to 35%35\%).
  3. Delivery for maternal or fetal indications (indicated preterm birth) (3030 to 35%35\%).
  4. Multifetal births (60%60\% of twins and 98%98\% of triplets are preterm).
Mechanisms of Disease
  • Uterine Overdistention: Multifetal pregnancy and hydramnios increase stress on the myometrium, stimulating an "inflammatory pulse." This triggers contraction-associated proteins (gap-junction proteins, oxytocin receptors, prostaglandin synthase) and the fetal endocrine cascade.
  • Cervical Dysfunction: Premature remodeling due to stromal matrix changes or loss of hyaluronan in the epithelia. Group B Streptococcus (GBS) can secrete hyaluronidase to aid bacterial ascension.
  • Infection: Subclinical intraamnionic infection is found in 2525 to 40%40\% of preterm births. Bacteria (often ascending through the cervix) trigger Toll-like receptors (TLRs), producing cytokines (IL-1β\beta, IL-6, IL-8, TNF-α\alpha).
    • Cytokine Actions: Prostaglandin formation, leukocyte recruitment, and production of Matrix Metalloproteinases (MMPs) which disrupt the structural integrity of membranes and the cervix.
  • Maternal-Fetal Stress: Psychosocial stress activates the placental-adrenal endocrine axis or premature cellular senescence, releasing uterotonic signals.

Contributing Factors to Preterm Birth

  • Prior Preterm Birth: The most significant risk factor. Risk is 33 times higher for recurrent preterm delivery. Recurrence often occurs within 22 weeks of the prior gestational age.
  • Lifestyle: Smoking, illicit drug use, extremes of maternal weight (underweight or obese), and heavy physical labor.
  • Genetics: Familial recurrence is suggested by variants in genes like EBF1EBF1, EEFSECEEFSEC, and AGTR2AGTR2.
  • Infection: Bacterial vaginosis (BV) is associated with preterm labor, though screening and treatment have not consistently prevented it. Periodontal disease (gingivitis) is also associated, but treatment does not lower the preterm birth rate.
  • Interpregnancy Interval: Intervals <18< 18 months and >59> 59 months are associated with increased risk.

Diagnosis of Preterm Labor

Clinical Presentation

Symptoms include regular contractions, pelvic pressure, menstrual-like cramps, and lower back pain. ACOG defines preterm labor as regular contractions accompanied by a change in cervical dilation/effacement or initial dilation of at least 2 cm2\,cm.

Predictive Biomarkers
  • Fetal Fibronectin (fFN): A glycoprotein reflecting stromal remodeling. Values >50 ng/mL> 50\,ng/mL are positive. It has low predictive performance in low-risk populations.
  • Placental Alpha Microglobulin-1 (PAMG-1): Emerged as superior to fFN in predicting birth within 77 days among symptomatic women.
  • Cervical Length (CL): Measured via transvaginal sonography. Progression toward shorter CL increases preterm risk. Screening is recommended for women with a history of prior spontaneous preterm birth.

Preterm Birth Prevention Strategies

Cervical Cerclage

Cerclage may be history-indicated (prior losses), ultrasound-indicated (short CL), or used as a "rescue" procedure. For singleton pregnancies with a prior preterm birth and CL <25 mm< 25\,mm before 2424 weeks, cerclage significantly improves outcomes.

Progestogen Compounds (The Progesterone Controversy)
  • 1717-Alpha Hydroxyprogesterone Caproate (1717-OHPC/Makena): Initially FDA-approved to prevent recurrent preterm birth based on an MFMU study. However, the subsequent PROLONG Trial (17081708 women) found no treatment benefit. In 20202020, the FDA proposed withdrawing Makena from the market.
  • Vaginal Progesterone: Studies (Fonseca, Hassan) suggested benefit for women with CL ≤15\le 15-20 mm20\,mm. However, the OPPTIMUM study found no long-term cognitive or immediate neonatal benefits.
Other Interventions
  • Aspirin: Low-dose aspirin (81 mg81\,mg) may reduce spontaneous preterm birth in nulliparous women, though current ACOG guidance only recommends it for those with preeclampsia risk.
  • Bed Rest: Evidence suggests bed rest is neither beneficial nor effective and may be harmful due to risks of thromboembolism and bone loss.
  • Cervical Pessaries: Arabin pessaries have shown inconsistent results and are currently recommended only within research protocols.

Management of PPROM

Natural History and Hospitalization

Latency (time from rupture to delivery) is inversely related to gestational age. Most women enter labor within a week of rupture. Management involves maternal/fetal surveillance and assessing the risk of chorioamnionitis vs. prematurity.

Pharmacological Management
  • Antibiotics: A 77-day regimen (e.g., intravenous ampicillin and erythromycin followed by oral amoxicillin and erythromycin) is recommended to prolong latency. Amoxicillin-clavulanate is avoided due to increased risks of neonatal NEC.
  • Corticosteroids: A single course is recommended between 240/724^{0/7} and 340/734^{0/7} weeks.
  • Magnesium Sulfate: Recommended for neuroprotection in pregnancies expected to deliver before 320/732^{0/7} weeks.

Management of Preterm Labor with Intact Membranes

Corticosteroid Therapy for Fetal Lung Maturation
  • Betamethasone: Two 12 mg12\,mg doses, 2424 hours apart.
  • Dexamethasone: Four 6 mg6\,mg doses, every 1212 hours.
  • Benefits: Lowers RDS, IVH, NEC, and mortality. A single "rescue" course may be considered if >7> 7 days have elapsed and delivery is imminent before 3434 weeks.
Magnesium Sulfate (Neuroprotection)

The BEAM Study (Rouse,2008Rouse, 2008) showed that magnesium sulfate (administered as a 6 g6\,g bolus followed by 2 g/hr2\,g/hr) significantly lowered risks for moderate to severe cerebral palsy in neonates delivered before 3232 weeks.

Tocolytic Therapy

Tocolytics are primarily used to delay delivery for 4848 hours to allow for corticosteroid administration.

  • β\beta-Adrenergic Agonists (Terbutaline): Side effects include maternal pulmonary edema and cardiac disturbances.
  • Calcium-Channel Blockers (Nifedipine): Safer and more effective than β\beta-agonists. Should not be used simultaneously with magnesium sulfate.
  • Prostaglandin Inhibitors (Indomethacin): Effective but limited to 4848 hours due to risks of oligohydramnios and ductus arteriosus closure.
  • Magnesium Sulfate: Used traditionally for labor arrest but largely abandoned at some centers (like Parkland) due to evidence of inefficacy for tocolysis.